Physician profile
Erin E Hazel
NPI 1205602596
$570.65
in general payments reported to CMS, 2019-2025
15 companies · $350 in 2025
The $350 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $221 · 2025: $350.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $571.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $570.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $90.07 | 2025 | Korlym |
| Shield Therapeutics INC | $67.83 | 2025 | |
| Lilly USA, LLC | $64.37 | 2024-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $53.23 | 2024 | |
| Novo Nordisk INC | $43.58 | 2024 | Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $43.02 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $29.48 | 2024 | Breztri |
| Redhill Biopharma INC. | $28.62 | 2025 | Talicia |
| Glaxosmithkline, LLC. | $27.63 | 2025 | Arexvy, Shingrix |
| Ironwood Pharmaceuticals, INC | $26.28 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $22.04 | 2025 | Zoryve |
| Janssen Pharmaceuticals, INC | $20.90 | 2024 | Invega Trinza, Invega Sustenna |
| Viiv Healthcare Company | $20.42 | 2025 | Apretude |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.05 | 2024 | Jardiance |
| Dexcom, INC. | $14.13 | 2024 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Erin Hazel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.